{"title":"Characterization of plant produced VHH antibodies against cobra venom toxins for antivenom therapy","authors":"Sarocha Vitayathikornnasak , Kaewta Rattanapisit , Ashwini Malla , Pipob Suwanchaikasem , Richard Strasser , Narach Khorattanakulchai , Kanokporn Pothisamutyothin , Wanatchaporn Arunmanee , Waranyoo Phoolcharoen","doi":"10.1016/j.btre.2024.e00841","DOIUrl":null,"url":null,"abstract":"<div><p>Cobra (<em>Naja kaouthia</em>) venom contains many toxins including α-neurotoxin (αNTX) and phospholipase A2 (PLA2), which can cause neurodegeneration, respiratory failure, and even death. The traditional antivenom derived from animal serum faces many challenges and limitations. Heavy-chain-only antibodies (HCAb), fusing V<sub>HH</sub> with human IgG Fc region, offer advantages in tissue penetration, antigen binding, and extended half-life. This research involved the construction and transient expression of two types of V<sub>HH</sub>-F<sub>C</sub> which are specific to α-Neurotoxin (V<sub>HH</sub>-αNTX-F<sub>C</sub>) and Phospholipase A2 (V<sub>HH</sub>-PLA2-F<sub>C</sub>) in <em>Nicotiana benthamiana</em> leaves. The recombinant HCAbs were incubated for up to six days to optimize expression levels followed by purification by affinity chromatography and characterization using LC/Q-TOF mass spectrometry (MS). Purified proteins demonstrated over 92 % sequence coverage and an average mass of around 82 kDa with a high-mannose N-glycan profile. An antigen binding assay showed that the V<sub>HH</sub>-αNTX-Fc has a greater ability to bind to crude venom than V<sub>HH</sub>-PLA2-Fc.</p></div>","PeriodicalId":38117,"journal":{"name":"Biotechnology Reports","volume":"42 ","pages":"Article e00841"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2215017X24000146/pdfft?md5=118770804465782939c653851a16cfe8&pid=1-s2.0-S2215017X24000146-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2215017X24000146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
引用次数: 0
Abstract
Cobra (Naja kaouthia) venom contains many toxins including α-neurotoxin (αNTX) and phospholipase A2 (PLA2), which can cause neurodegeneration, respiratory failure, and even death. The traditional antivenom derived from animal serum faces many challenges and limitations. Heavy-chain-only antibodies (HCAb), fusing VHH with human IgG Fc region, offer advantages in tissue penetration, antigen binding, and extended half-life. This research involved the construction and transient expression of two types of VHH-FC which are specific to α-Neurotoxin (VHH-αNTX-FC) and Phospholipase A2 (VHH-PLA2-FC) in Nicotiana benthamiana leaves. The recombinant HCAbs were incubated for up to six days to optimize expression levels followed by purification by affinity chromatography and characterization using LC/Q-TOF mass spectrometry (MS). Purified proteins demonstrated over 92 % sequence coverage and an average mass of around 82 kDa with a high-mannose N-glycan profile. An antigen binding assay showed that the VHH-αNTX-Fc has a greater ability to bind to crude venom than VHH-PLA2-Fc.
Biotechnology ReportsImmunology and Microbiology-Applied Microbiology and Biotechnology
CiteScore
15.80
自引率
0.00%
发文量
79
审稿时长
55 days
期刊介绍:
Biotechnology Reports covers all aspects of Biotechnology particularly those reports that are useful and informative and that will be of value to other researchers in related fields. Biotechnology Reports loves ground breaking science, but will also accept good science that can be of use to the biotechnology community. The journal maintains a high quality peer review where submissions are considered on the basis of scientific validity and technical quality. Acceptable paper types are research articles (short or full communications), methods, mini-reviews, and commentaries in the following areas: Healthcare and pharmaceutical biotechnology Agricultural and food biotechnology Environmental biotechnology Molecular biology, cell and tissue engineering and synthetic biology Industrial biotechnology, biofuels and bioenergy Nanobiotechnology Bioinformatics & systems biology New processes and products in biotechnology, bioprocess engineering.